Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 8 | 2022 | 297 | 3.180 |
Why?
|
| Myocardial Infarction | 9 | 2025 | 215 | 3.050 |
Why?
|
| Heart Failure | 7 | 2026 | 403 | 2.620 |
Why?
|
| Hospitalization | 8 | 2026 | 816 | 1.710 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2025 | 155 | 1.640 |
Why?
|
| Medication Adherence | 5 | 2024 | 235 | 1.510 |
Why?
|
| Stroke Volume | 3 | 2024 | 110 | 1.470 |
Why?
|
| Cholesterol, LDL | 4 | 2025 | 113 | 1.350 |
Why?
|
| African Americans | 5 | 2020 | 394 | 1.240 |
Why?
|
| Cardiac Rehabilitation | 2 | 2026 | 8 | 1.210 |
Why?
|
| Cardiovascular Diseases | 4 | 2026 | 520 | 1.170 |
Why?
|
| Home Care Services | 2 | 2026 | 35 | 1.160 |
Why?
|
| Male | 27 | 2026 | 9556 | 1.160 |
Why?
|
| Proprotein Convertase 9 | 2 | 2019 | 2 | 1.140 |
Why?
|
| Hypertension | 6 | 2026 | 475 | 1.120 |
Why?
|
| Female | 27 | 2026 | 12193 | 1.040 |
Why?
|
| Middle Aged | 19 | 2026 | 7515 | 1.030 |
Why?
|
| Humans | 32 | 2026 | 16832 | 1.030 |
Why?
|
| Aged | 22 | 2026 | 5901 | 0.980 |
Why?
|
| Heart Diseases | 1 | 2026 | 71 | 0.940 |
Why?
|
| Hypercholesterolemia | 1 | 2025 | 24 | 0.910 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2023 | 116 | 0.900 |
Why?
|
| Referral and Consultation | 1 | 2026 | 147 | 0.890 |
Why?
|
| Safety-net Providers | 1 | 2025 | 52 | 0.880 |
Why?
|
| Physicians, Primary Care | 1 | 2025 | 63 | 0.860 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 197 | 0.810 |
Why?
|
| Natural Language Processing | 1 | 2024 | 60 | 0.790 |
Why?
|
| Patient Compliance | 1 | 2025 | 262 | 0.790 |
Why?
|
| United States | 15 | 2026 | 3858 | 0.750 |
Why?
|
| Retrospective Studies | 13 | 2026 | 2463 | 0.700 |
Why?
|
| Politics | 1 | 2020 | 9 | 0.650 |
Why?
|
| Incidence | 8 | 2026 | 1229 | 0.640 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 213 | 0.620 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 677 | 0.620 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 2 | 0.610 |
Why?
|
| Lipoprotein(a) | 1 | 2019 | 5 | 0.610 |
Why?
|
| Adult | 12 | 2026 | 7255 | 0.600 |
Why?
|
| Stress, Psychological | 1 | 2020 | 136 | 0.590 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 56 | 0.570 |
Why?
|
| Perception | 1 | 2019 | 53 | 0.570 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 42 | 0.560 |
Why?
|
| Self Report | 2 | 2017 | 248 | 0.560 |
Why?
|
| Forecasting | 1 | 2019 | 67 | 0.560 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 515 | 0.520 |
Why?
|
| Cognition Disorders | 1 | 2017 | 30 | 0.520 |
Why?
|
| Genetic Variation | 1 | 2017 | 67 | 0.520 |
Why?
|
| Risk Factors | 9 | 2025 | 3108 | 0.500 |
Why?
|
| Cognition | 1 | 2017 | 90 | 0.490 |
Why?
|
| Aged, 80 and over | 8 | 2026 | 1887 | 0.490 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 189 | 0.490 |
Why?
|
| Insurance Coverage | 1 | 2017 | 102 | 0.470 |
Why?
|
| Ethnic Groups | 1 | 2019 | 418 | 0.470 |
Why?
|
| California | 5 | 2026 | 2244 | 0.460 |
Why?
|
| Continental Population Groups | 1 | 2017 | 255 | 0.450 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 80 | 0.440 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 54 | 0.380 |
Why?
|
| Age Factors | 4 | 2024 | 814 | 0.370 |
Why?
|
| Time Factors | 4 | 2026 | 989 | 0.370 |
Why?
|
| Sex Factors | 3 | 2024 | 560 | 0.350 |
Why?
|
| Phenotype | 3 | 2026 | 105 | 0.340 |
Why?
|
| Pandemics | 2 | 2023 | 289 | 0.320 |
Why?
|
| Adolescent | 6 | 2026 | 3464 | 0.320 |
Why?
|
| Antihypertensive Agents | 2 | 2024 | 157 | 0.310 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 51 | 0.300 |
Why?
|
| Cohort Studies | 5 | 2023 | 2396 | 0.290 |
Why?
|
| Young Adult | 5 | 2026 | 2456 | 0.280 |
Why?
|
| Prevalence | 3 | 2023 | 785 | 0.270 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 1233 | 0.270 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2026 | 57 | 0.230 |
Why?
|
| Medicare | 3 | 2024 | 188 | 0.220 |
Why?
|
| Treatment Outcome | 2 | 2026 | 1098 | 0.220 |
Why?
|
| Interviews as Topic | 1 | 2025 | 305 | 0.210 |
Why?
|
| Proportional Hazards Models | 2 | 2026 | 657 | 0.210 |
Why?
|
| Quality of Health Care | 1 | 2026 | 249 | 0.200 |
Why?
|
| Life Style | 1 | 2025 | 305 | 0.200 |
Why?
|
| Prospective Studies | 4 | 2023 | 1186 | 0.200 |
Why?
|
| Residence Characteristics | 1 | 2025 | 244 | 0.200 |
Why?
|
| Retinal Diseases | 1 | 2023 | 6 | 0.200 |
Why?
|
| Disease Progression | 1 | 2024 | 252 | 0.200 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2023 | 20 | 0.200 |
Why?
|
| Diabetic Retinopathy | 1 | 2023 | 17 | 0.190 |
Why?
|
| Telemedicine | 1 | 2026 | 190 | 0.180 |
Why?
|
| Diabetes Mellitus | 1 | 2026 | 445 | 0.170 |
Why?
|
| Acute Disease | 1 | 2022 | 144 | 0.170 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 1204 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 13 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2026 | 702 | 0.160 |
Why?
|
| Child | 2 | 2026 | 2433 | 0.160 |
Why?
|
| Prognosis | 2 | 2020 | 568 | 0.150 |
Why?
|
| Rosuvastatin Calcium | 1 | 2019 | 4 | 0.150 |
Why?
|
| Inpatients | 1 | 2020 | 78 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2020 | 145 | 0.150 |
Why?
|
| Outpatients | 1 | 2020 | 99 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 46 | 0.150 |
Why?
|
| Drug Utilization | 1 | 2019 | 112 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2026 | 1047 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1058 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 157 | 0.140 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 47 | 0.130 |
Why?
|
| Law Enforcement | 1 | 2017 | 2 | 0.130 |
Why?
|
| HIV Infections | 1 | 2023 | 708 | 0.130 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 15 | 0.130 |
Why?
|
| Biomarkers | 1 | 2017 | 284 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 137 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 319 | 0.120 |
Why?
|
| Comorbidity | 2 | 2020 | 516 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 346 | 0.070 |
Why?
|
| Patient Discharge | 2 | 2019 | 152 | 0.060 |
Why?
|
| Hawaii | 1 | 2026 | 62 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2026 | 291 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2026 | 229 | 0.060 |
Why?
|
| Length of Stay | 1 | 2026 | 169 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2026 | 134 | 0.050 |
Why?
|
| Registries | 1 | 2026 | 449 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 571 | 0.050 |
Why?
|
| Fumarates | 1 | 2023 | 4 | 0.050 |
Why?
|
| Adenine | 1 | 2023 | 8 | 0.050 |
Why?
|
| Tenofovir | 1 | 2023 | 18 | 0.050 |
Why?
|
| Retreatment | 1 | 2020 | 2 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 39 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 207 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 64 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 653 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2020 | 242 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 400 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 294 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 410 | 0.030 |
Why?
|
| Contrast Sensitivity | 1 | 2017 | 1 | 0.030 |
Why?
|
| Automobile Driving | 1 | 2017 | 9 | 0.030 |
Why?
|
| Alabama | 1 | 2017 | 22 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 110 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 332 | 0.030 |
Why?
|
| Independent Living | 1 | 2017 | 24 | 0.030 |
Why?
|
Concepts
(133)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(14)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->